Regulation of leptin receptor expression in human papillary thyroid cancer cells

Biomedicine and Pharmacotherapy

Volumn 66, Issue 6, 2012, Pages 469-473

  Cheng, Shih Ping ^a,b,d   Liu, Chien Liang ^a,c   Hsu, Yi Chiung ^e   Chang, Yuan Ching ^a   Huang, Shih Yuan ^a   Lee, Jie Jen ^a,b,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

Epigenetic regulation; Insulin; Leptin receptor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; INSULIN RECEPTOR; LEPTIN RECEPTOR; TRICHOSTATIN A;

ARTICLE; CANCER CELL; CATALYSIS; CELL EXPANSION; CELL HYPOXIA; CELL STRUCTURE; CHROMATIN; CONTROLLED STUDY; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; THYROID CARCINOMA; UPREGULATION;

BLOTTING, WESTERN; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA, NEOPLASM; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASM PROTEINS; OSMOLAR CONCENTRATION; RECEPTORS, LEPTIN; THYROID NEOPLASMS; UP-REGULATION;

EID: 84866157843     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.03.008     Document Type: Article

References (41)

1. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7:569-580.
2. Kitahara C.M., Platz E.A., Freeman L.E., Hsing A.W., Linet M.S., Park Y., et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011, 20:464-472.
3. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
4. van Kruijsdijk R.C., van der Wall E., Visseren F.L. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009, 18:2569-2578.
5. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
6. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263-1271.
7. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006, 393:7-20.
8. Hsu H.T., Chang Y.C., Chiu Y.N., Liu C.L., Chang K.J., Guo I.C. Leptin interferes with adrenocorticotropin/3',5'-cyclic adenosine monophosphate (cAMP) signaling, possibly through a Janus kinase 2-phosphatidylinositol 3-kinase/Akt-phosphodiesterase 3-cAMP pathway, to down-regulate cholesterol side-chain cleavage cytochrome P450 enzyme in human adrenocortical NCI-H295 cell line. J Clin Endocrinol Metab 2006, 91:2761-2769.
9. Chen C., Chang Y.C., Liu C.L., Chang K.J., Guo I.C. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 2006, 98:121-132.
10. Chen C., Chang Y.C., Liu C.L., Liu T.P., Chang K.J., Guo I.C. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007, 14:513-529.
11. Liu C.L., Chang Y.C., Cheng S.P., Chern S.R., Yang T.L., Lee J.J., et al. The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology 2007, 72:75-81.
12. Cheng S.P., Doherty G.M., Chang Y.C., Liu C.L. Leptin: the link between overweight and primary hyperparathyroidism?. Med Hypotheses 2011, 76:94-96.
13. Cheng S.P., Chi C.W., Tzen C.Y., Yang T.L., Lee J.J., Liu T.P., et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010, 147:847-853.
14. Cheng S.P., Yin P.H., Chang Y.C., Lee C.H., Huang S.Y., Chi C.W. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep 2010, 23:1721-1727.
15. Cheng S.P., Yin P.H., Hsu Y.C., Chang Y.C., Huang S.Y., Lee J.J., et al. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep 2011, 26:1265-1271.
16. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341.
17. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97.
18. Momparler R.L. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin Hematol 2005, 42:S9-S16.
19. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
20. Mathew O.P., Ranganna K., Yatsu F.M. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed Pharmacother 2010, 64:733-740.
21. Codd R., Braich N., Liu J., Soe C.Z., Pakchung A.A. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol 2009, 41:736-739.
22. Frittitta L., Sciacca L., Catalfamo R., Ippolito A., Gangemi P., Pezzino V., et al. Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis?. Cancer 1999, 85:492-498.
23. Garofalo C., Koda M., Cascio S., Sulkowska M., Kanczuga-Koda L., Golaszewska J., et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006, 12:1447-1453.
24. Hikita M., Bujo H., Hirayama S., Takahashi K., Morisaki N., Saito Y. Differential regulation of leptin receptor expression by insulin and leptin in neuroblastoma cells. Biochem Biophys Res Commun 2000, 271:703-709.
25. Koda M., Sulkowska M., Kanczuga-Koda L., Cascio S., Colucci G., Russo A., et al. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. Ann Oncol 2007, 18(Suppl 6:):vi116-vi119.
26. Koda M., Kanczuga-Koda L., Sulkowska M., Surmacz E., Sulkowski S. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. BMC Cancer 2010, 10:320.
27. Grosfeld A., Andre J., Hauguel-De Mouzon S., Berra E., Pouyssegur J., Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002, 277:42953-42957.
28. Liu X.H., Kirschenbaum A., Yao S., Stearns M.E., Holland J.F., Claffey K., et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999, 17:687-694.
29. Sheffield L. Malignant transformation of mammary epithelial cells increases expression of leptin and leptin receptor. Endocr Res 2008, 33:111-118.
30. Paik S.S., Jang S.M., Jang K.S., Lee K.H., Choi D., Jang S.J. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009, 16:297-303.
31. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
32. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
33. Russo D., Damante G., Puxeddu E., Durante C., Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 2011, 46:R73-R81.
34. Alvarez-Nunez F., Bussaglia E., Mauricio D., Ybarra J., Vilar M., Lerma E., et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006, 16:17-23.
35. Vivaldi A., Miasaki F.Y., Ciampi R., Agate L., Collecchi P., Capodanno A., et al. Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. Mol Cell Endocrinol 2009, 307:142-148.
36. Puppin C., D'Aurizio F., D'Elia A.V., Cesaratto L., Tell G., Russo D., et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005, 146:3967-3974.
37. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
38. Woyach J.A., Kloos R.T., Ringel M.D., Arbogast D., Collamore M., Zwiebel J.A., et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009, 94:164-170.
39. Aschebrook-Kilfoy B., Sabra M.M., Brenner A., Moore S.C., Ron E., Schatzkin A., et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 2011, 21:957-963.
40. Carroll P.A., Healy L., Lysaght J., Boyle T., Reynolds J.V., Kennedy M.J., et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mol Carcinog 2011, 50:643-651.
41. Otvos L., Kovalszky I., Riolfi M., Ferla R., Olah J., Sztodola A., et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 2011, 47:1578-1584.